04:10 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Dutch NASH play NorthSea debuts with €25M

On Dec. 12, former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round...
09:15 , Dec 12, 2017 |  BC Extra  |  Financial News

Dutch NASH play NorthSea debuts with €25M

Former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round led by Forbion...
21:44 , Dec 2, 2016 |  BioCentury  |  Finance

Tapping Belgium

V-Bio Ventures plans to use its first fund to fuel the creation of spinouts from the Flanders Institute for Biotechnology (VIB) , a government-funded translational life sciences research institute based in Belgium. Founded in 2015,...
07:00 , Sep 7, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/4 cls Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Piper Jaffray Charles Duncan Upgrade Overweight (from neutral) 3% $39.46 Duncan upgraded and maintained...
02:23 , Apr 16, 2015 |  BC Extra  |  Company News

Management tracks

Merck KGaA (Xetra:MRK) said Udit Batra will become head of its combined life sciences business, pending completion in mid-2015 of its planned acquisition of Sigma-Aldrich Corp. (NASDAQ:SIAL). Batra has been CEO and president of Merck...
08:00 , Feb 3, 2014 |  BioCentury  |  Regulation

Lipid advice in Europe

A lack of clarity about requirements for cardiovascular safety and outcomes data in updated EMA guidance means companies developing lipid-modulating therapies will need to seek individual advice from the European regulator as early as possible...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

BASF, Verenium deal

Chemicals company BASF completed its tender offer and the acquisition of Verenium for $4 per share in cash in a deal BASF says values Verenium at about $62 million (see BioCentury, Sept. 30). BASF AG...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

BASF, Verenium deal

Chemicals company BASF will acquire Verenium for $4 per share in cash in a deal BASF says values Verenium at about $62 million. Verenium develops and commercializes enzymes used in industrial processes. The price is...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Teva, BASF, Par Pharmaceutical endocrine/metabolic news

The U.S. Court of Appeals for the Federal Circuit reversed in part a lower court's 2012 ruling upholding U.S. Patent Nos. 5,656,667 and 5,502,077 covering Pronova Biopharma ASA 's lipid-lowering drug, Lovaza . Chemicals company...
08:00 , Mar 4, 2013 |  BioCentury  |  Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...